The peer review publication, Oncotarget, has seen a lot of doctors come together to find the best treatment for cancer. They are working together to make sure they are getting treatment options and doing their best to provide other doctors with the things they need to help come up with a cure for cancer. Recently, Research Gate made sure they were highlighting Oncotarget. They knew the publication was doing their best to find information on the things they had to offer and that’s what made them realize they could publish more information on what was going on in the industry. Looking at these opportunities has given places like Research Gate the chance to realize there are different options they can use and different things they can make easier on the people who they are doing business with. It has allowed them the chance to grow their business while also helping other people. Watch this video on Youtube.
As Oncotarget has grown and the doctor who runs the publication has learned more about what he can do to help people, there have been many more opportunities for people to realize there is a lot of help the publication can provide. For those who use Oncotarget, the doctors know what they’re doing and how they’re doing everything the right way. They also know they are able to get the best deals out of everything they have in the industry. When people look at these options, they can see how much things have changed and how they can actually have a positive impact on cancer treatment.
As long as Oncotarget continues to grow and add more doctors to the mix, they are going to keep coming up with new results and with the options other people have to use with these results. The way they can do these things is by looking at treatment and seeing how it can have a positive effect on others. There have been many chances people can use to make Oncotarget the best it can be and to make it a better publication. For doctors, this can be beneficial and can be a necessary part of the business. Learn more about Oncotarget at Eurekalert.org.
You may not know Eric Lefkofsky’s name but chances are you have used services from one of the many businesses the ambitious entrepreneur has helped build from the group up.Lefkofsky is best known as co-founder and CEO of two very important companies: Groupon and Tempus. The latter is a groundbreaking genome sequencing company that was started to help doctors understand the DNA makeup of the patients they are treating. Combining genome mapping and analytics, Tempus delivers a map of a patient’s molecular structure to help guide physicians in the treatment of various types of cancers.
Lefkofsky started his entrepreneurial endeavors at the University of Michigan where he sold carpets in his spare time to raise money. After graduating from law school, Eric and a college friend borrowed money to fund a clothing company in Madison, Wisconsin. Over the next few years Lefkofsky would start a number of businesses that would provide anything from printing services to shipping logistics.One of Lefkofsky’s biggest breaks came in 2007 when he co-founded ThePoint, which would later change its name to Groupon. Groupon is an online marketplace that sells promotional deals for restaurants, shops, and social events.
In 2011 Groupon raised close to $1 billion in private funding, and Lefkofsky assumed the role of CEO shortly afterwards in 2013.One reason why he is so successful is from his grasp on the theory of “Accelerated Disruption”, a subject that he published a book on under the same name. Accelerated Disruption is the idea that technology and business moves at the speed of light, and an entrepreneur that thinks he may have struck gold with a business idea can soon be challenged by others with similar ideas due to the rapid growth of science and technology.In addition to Lefkofsky’s lucrative business career, the entrepreneur engages in philanthropy through the Lefkofsky Family Foundation. The Foundation’s mission is to provide scientific and educational opportunities to communities in need around the world, and focuses primarily on children. The Foundation has contributed to the funding of dozens of other philanthropic organizations across the planet.
Tempus is the name of an app that focuses on cancer. It was created by Eric Lefkofsky, the mastermind behind Groupon, a wildly popular online coupon marketing company. Tempus is aiming to provide University of Chicago physicians with access to information that can aid them in the successful treatment of breast cancer. Tempus is headquartered in the Windy City. The people behind the app recently revealed that they’re teaming up with the University of Chicago Medicine. They’re planning on offering molecular assessments and sequencing to the breast cancer experts who work for the University of Chicago.
This information will enable them to established individualized treatment courses for all of their patients. Tempus indicates that it’s going to evaluate information from roughly 1,000 individuals to assist physicians who want to learn more about patterns that can help forecast potential patient reactions. Tempus states that its priority is to enhance breast cancer treatment techniques. It also is to strengthen outcomes for patients.Eric Lefkofsky is a prominent entrepreneur who comes from the United States. He was born in early September of 1969. He’s a native of Southfield, Michigan and is currently married to a woman named Elizabeth. Lefkofsky is a graduate of the University of Michigan. He earned a Juris Doctor degree from the institution of higher learning back in 1993.
One of Lefkofsky’s earliest jobs involved the carpet sales world. He got involved in carpet sales when he was still a student at the University of Michigan. Once he completed law school, he joined forces with a buddy by the name of Brad Keywell. The pair got loans from family members and used them to purchase an apparel firm from Madison, Wisconsin. It was called “Brandon Apparel.” Lefkofsky’s career has been unstoppable since that time. He landed his position as Groupon CEO in the summer of 2013. He started Tempus three short years later in 2016 as well.
Clay Siegall is a renowned scientist who has been focused on conducting research to determine cancer cures. He is one of the co-founders of Seattle Genetics Company and also serves it as president and chairperson. The organization has been focused on creating new treatments for cancer, and it was founded in 1998. Siegall is highly skilled and experienced in the field. He has been supporting his company to focus on scientific innovations that can help in curing cancer patients. Clay has excellent administration skills and has guided Seattle Genetics Company to be productive. The firm has presently developed antibody-drug conjugates that have been essential in the treatment of cancer.
Clay has strived to ensure that his company is permitted to participate in different technologies such as Roche, AbbVie, Pfizer, and GlaxoSmithKline. In 2014, he was chosen by Ultragenyx to serve as a member of its board. Dr. Siegall had worked for various organizations before he established Seattle Genetics Company. As from 1991 to 1997, he served as an employee of the Bristol-Myers Squibb Pharmaceutical Research Institute. He also worked for foundations such as the National Cancer Institute and the National Cancer Institute from 1988 to 1991. Clay has been hired by BioPharmaceuticals and Mirna Therapeutics, which are leading biotechnology companies. He serves the two organizations as a board member. Siegall was awarded a Bachelor of Science in Zoology degree from the University of Maryland, and he later enrolled at the George Washington University, where he graduated with a Ph.D. in Genetics.
Mirna Therapeutics chose Clay Siegall to serve it as an outside board member as from January 2013. He has sufficient experience in the pharmaceutical industry his expertise is highly needed by the company. Siegall played a significant role in the creation of micro-RNA-based therapeutics. He believes that the therapeutics are crucial in conducting cancer research. According to him, the scientists that have been hired by Mirna are highly productive. Clay was grateful for being chosen as an outside director of the firm. He has devoted himself to working with the company’s management to develop reliable cancer cures. Siegall has written various books, and he holds 15 patents for his work.